113 related articles for article (PubMed ID: 15078134)
81. Targeting FLT3 kinase in acute myelogenous leukemia: progress, perils, and prospects.
Heinrich MC
Mini Rev Med Chem; 2004 Mar; 4(3):255-71. PubMed ID: 15032673
[TBL] [Abstract][Full Text] [Related]
82. Therapeutic intervention in leukemias that express the activated fms-like tyrosine kinase 3 (FLT3): opportunities and challenges.
Sternberg DW; Licht JD
Curr Opin Hematol; 2005 Jan; 12(1):7-13. PubMed ID: 15604885
[TBL] [Abstract][Full Text] [Related]
83. FLT3 tyrosine kinase as a target in acute leukemias.
Griffin JD
Hematol J; 2004; 5 Suppl 3():S188-90. PubMed ID: 15190306
[No Abstract] [Full Text] [Related]
84. FLT3: ITDoes matter in leukemia.
Levis M; Small D
Leukemia; 2003 Sep; 17(9):1738-52. PubMed ID: 12970773
[TBL] [Abstract][Full Text] [Related]
85. Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia.
Sawyers CL
Cancer Cell; 2002 Jun; 1(5):413-5. PubMed ID: 12124170
[TBL] [Abstract][Full Text] [Related]
86. Flt3 in acute myelogenous leukemia: biology, prognosis, and therapeutic implications.
Voutsadakis IA
Med Oncol; 2003; 20(4):311-24. PubMed ID: 14716027
[TBL] [Abstract][Full Text] [Related]
87. Flt3 receptor tyrosine kinase as a drug target in leukemia.
Schmidt-Arras D; Schwäble J; Böhmer FD; Serve H
Curr Pharm Des; 2004; 10(16):1867-83. PubMed ID: 15180525
[TBL] [Abstract][Full Text] [Related]
88. FLT3 and its role in the pathogenesis of acute myeloid leukaemia.
Reilly JT
Leuk Lymphoma; 2003 Jan; 44(1):1-7. PubMed ID: 12691136
[TBL] [Abstract][Full Text] [Related]
89. FLT3-activating mutations in acute promyelocytic leukaemia: a rationale for risk-adapted therapy with FLT3 inhibitors.
Gilliland DG
Best Pract Res Clin Haematol; 2003 Sep; 16(3):409-17. PubMed ID: 12935959
[TBL] [Abstract][Full Text] [Related]
90. FLT3 tyrosine kinase as a target molecule for selective antileukemia therapy.
Naoe T; Kiyoe H; Yamamoto Y; Minami Y; Yamamoto K; Ueda R; Saito H
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S27-30. PubMed ID: 11587362
[TBL] [Abstract][Full Text] [Related]
91. [Mutations of the gene coding for the receptor tyrosine kinase FLT3 in acute myeloid leukemia. Significance as the disease-specific molecular marker for diagnosis, prognosis and innovative therapy approaches].
Spiekermann K; Hiddemann W; Schnittger S
Dtsch Med Wochenschr; 2005 Apr; 130(16):1020-5. PubMed ID: 15830315
[No Abstract] [Full Text] [Related]
92. Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.
Sattler M; Scheijen B; Weisberg E; Griffin JD
Adv Exp Med Biol; 2003; 532():121-40. PubMed ID: 12908554
[TBL] [Abstract][Full Text] [Related]
93. FLT3 in human hematologic malignancies.
Kiyoi H; Naoe T
Leuk Lymphoma; 2002 Aug; 43(8):1541-7. PubMed ID: 12400596
[TBL] [Abstract][Full Text] [Related]
94. FLT-3: a new focus in the understanding of acute leukemia.
Markovic A; MacKenzie KL; Lock RB
Int J Biochem Cell Biol; 2005 Jun; 37(6):1168-72. PubMed ID: 15778081
[TBL] [Abstract][Full Text] [Related]
95. Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.
Garcia JS; Percival ME
Drugs Today (Barc); 2017 Oct; 53(10):531-543. PubMed ID: 29286055
[TBL] [Abstract][Full Text] [Related]
96. The clinical development of FLT3 inhibitors in acute myeloid leukemia.
Knapper S
Expert Opin Investig Drugs; 2011 Oct; 20(10):1377-95. PubMed ID: 21895538
[TBL] [Abstract][Full Text] [Related]
97. FLT3 inhibitors for the treatment of acute myeloid leukemia.
Wiernik PH
Clin Adv Hematol Oncol; 2010 Jun; 8(6):429-36, 444. PubMed ID: 20733555
[TBL] [Abstract][Full Text] [Related]
98. [FLT3 kinase inhibitors for the treatment of acute leukemia].
Kiyoi H
Rinsho Ketsueki; 2010 Jun; 51(6):384-9. PubMed ID: 20622483
[No Abstract] [Full Text] [Related]
99. FLT3 inhibitors in acute myeloid leukemia: Current and future.
Thomas CM; Campbell P
J Oncol Pharm Pract; 2019 Jan; 25(1):163-171. PubMed ID: 30270754
[TBL] [Abstract][Full Text] [Related]
100. FLT3 mutations: biology and treatment.
Small D
Hematology Am Soc Hematol Educ Program; 2006; ():178-84. PubMed ID: 17124058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
